FDA Signs Off on Pivotal Phase 3 Design for Cognition's DLB Drug
CGTX sits 45% above its 52-week low of $0.55.
Summary
Cognition Therapeutics said the FDA agreed on the key design elements of a pivotal Phase 3 trial of zervimesine (CT1812) in dementia with Lewy bodies: patient selection, dose, duration and endpoints. The study will test 100 mg once daily against placebo for nine months, with NPI-2 as the primary endpoint and ADCS-ADL as the key secondary. That moves the program from Phase 2 signals onto a registrational path in an indication with no approved treatments. The company's August 10-Q had already flagged FDA alignment on the trial design; this release fills in the specifics. For a micro-cap with a sub-$1 stock, a clean, well-powered Phase 3 readout on NPI-2 and ADCS-ADL is the single biggest value driver ahead.
At the time of this announcement, CGTX was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $71M. The 52-week trading range was $0.55 to $1.93. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.